Monday, December 10 - Scientific Presentations

ASH 2001
A Randomized Trail of Fludarabine and Mitoxantrone Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma
Acute Myeloid Leukemia in Adolescents and Young Adults (AYAs): A Comparison of Outcomes Between Patients Treated on Childhood or Adult Protocols
Air Travel, Prothrombotic Mutations and Venous Thrombosis: The MEGA Study
CHEOP (Chop + Etoposide): the New Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non-Hodgkin's Lymphoma (NHL)
CHOP Alone Compared to CHOP Plus Radiotherapy for Early Stage Aggressive Non-Hodgkin's Lymphomas: Update of the Southwest Oncology Group (SWOG) Randomized Trial
Concurrent Fludarabine and Total Body Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkin's Lymphoma (NHL): A Phase I Trial.
Cytotoxicity of Mevastatin and Other Cholesterol Modulators in Acute Myeloid Leukemia
Early Restaging Positron Emmision Tomography (PET) with 18F-Fluorodeoxyglucose (18FDG)Predicts Outcome in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL)
Final Report of E1484: CHOP vs CHOP + Radiotherapy (RT) for Limited Stage Diffuse Aggressive Lymphoma
Gastric MALT Lymphomas Prospective LY03 Randomized Cooperative Trial: Preliminary Results of the Molecular Follow-up
High Levels of Soluble CD20 (sCD20) in patients with Non-Hodgkin's Lymphoma (NHL): Correlation with Clinical Behavior and Contrast with Patients with Hodgkin's Disease (HD)
Multiple Resistance Mechanisms Identified through Studies of Cell Lines Derived from Chronic Myelogenous Leukemia Patients Progressing on STI-571 Therapy
Requestioning the Role of Prolonged Maintenance Chemotherapy in AML: Randomized Trial by the German AML Cooperative Group Updated.
t(11;18) Is a marker for All Stage Gastric MALT Lymphomas That Will Not Respond o H. Pylori Eradication
The Combination of Low D-Dimer Concentration and Non-High Clinical Probability Score is a Safe Strategy to Exclude Deep Venous Thrombosis
Thrive I: Efficacy and Tolerability of the Novel, Oral Direct Thrombin Inhibitor Ximelagatran Compared with Standard Therapy for the Treatment of Acute Deep Venous Thrombosis

News
ASH: CALR Mutations ID'd in Myeloproliferative Neoplasms

Dec 11, 2013 - Many patients with myeloproliferative neoplasms without mutations in the Janus kinase 2 gene (JAK2) or in the thrombopoietin receptor gene (MPL) have mutations in the CALR gene encoding calreticulin, according to two studies published online Dec. 10 in the New England Journal of Medicine. The research was published to coincide with presentation at the annual meeting of the American Society of Hematology, held from Dec. 7 to 10 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More